Inhaled Insulin: An Overview
Article Figures & Tables
Tables
- Table 1.
Summary of Phase 2 Trials
Patient Type N Duration of study (not including run-in period) Treatment arm/change in HbA1c from baseline Reference Type 2 51 3 months • Inhaled insulin/0.7% 12 • Subcutaneous insulin/0.7% Type 2 62 3 months • Oral agent/0.13% 13 • Oral agent plus inhaled insulin/2.28% Type 1 70 3 months • Subcutaneous insulin (2–3 injections/day)/0.83% 14 • Inhaled insulin plus subcutaneous insulin (once daily)/0.64%